Ocuphire Pharma Pre-Paid Expenses 2010-2024 | IRD

Ocuphire Pharma pre-paid expenses from 2010 to 2024. Pre-paid expenses can be defined as a current asset created by prepayment of costs and expenses for which the benefits will occur at a future date.
Ocuphire Pharma Annual Pre-Paid Expenses
(Millions of US $)
2023 $1
2022 $1
2021 $1
2020 $1
2019 $0
2018 $1
2017 $1
2016 $1
2015 $1
2014 $1
2013 $1
2012 $0
2011 $0
2010 $1
2009 $0
Ocuphire Pharma Quarterly Pre-Paid Expenses
(Millions of US $)
2024-06-30 $1
2024-03-31 $2
2023-12-31 $1
2023-09-30 $0
2023-06-30 $1
2023-03-31 $1
2022-12-31 $1
2022-09-30 $1
2022-06-30 $1
2022-03-31 $1
2021-12-31 $1
2021-09-30 $1
2021-06-30 $1
2021-03-31 $1
2020-12-31 $1
2020-09-30 $1
2020-06-30 $1
2020-03-31 $0
2019-12-31 $0
2019-09-30 $1
2019-06-30 $1
2019-03-31 $1
2018-12-31 $1
2018-09-30 $1
2018-06-30 $1
2018-03-31 $1
2017-12-31 $1
2017-09-30 $1
2017-06-30 $1
2017-03-31 $1
2016-12-31 $1
2016-09-30 $1
2016-06-30 $1
2016-03-31 $1
2015-12-31 $1
2015-09-30 $1
2015-06-30 $1
2015-03-31 $1
2014-12-31 $1
2014-09-30 $1
2014-06-30 $1
2014-03-31 $1
2013-12-31 $1
2013-09-30 $1
2013-06-30 $0
2013-03-31 $0
2012-12-31 $0
2012-09-30 $0
2012-06-30 $0
2012-03-31 $0
2011-12-31 $0
2011-09-30 $0
2011-06-30 $0
2011-03-31 $1
2010-12-31 $1
2010-09-30 $0
2010-06-30 $1
2010-03-31 $0
2009-12-31 $0
2009-09-30 $0
2009-06-30 $0
2009-03-31 $0
Sector Industry Market Cap Revenue
$0.000B $0.000B
Ocuphire Pharma Inc. is a clinical-stage ophthalmic biopharmaceutical company. It is focused on developing and commercializing therapies for the treatment of several eye disorders. The company's product pipeline includes Nyxol Eye Drops(R) and APX3330. Ocuphire Pharma Inc., formerly known as Rexahn Pharmaceuticals Inc., is based in FARMINGTON HILLS, Mich.
Stock Name Country Market Cap PE Ratio
Fanhua (AIFU) China $0.086B 2.07
Top KingWin (WAI) China $0.008B 0.00
S&W Seed (SANW) United States $0.006B 0.00
Invo BioScience (NAYA) United States $0.004B 0.00